Literature DB >> 35442400

The Oncogenic PI3K-Induced Transcriptomic Landscape Reveals Key Functions in Splicing and Gene Expression Regulation.

Erik Ladewig1,2, Flavia Michelini1, Komal Jhaveri3, Pau Castel1,4, Javier Carmona1, Lauren Fairchild5,6, Adler G Zuniga7, Amaia Arruabarrena-Aristorena1,8,9,10, Emiliano Cocco1,11, Ryan Blawski7, Srushti Kittane12, Yuhan Zhang12, Mirna Sallaku1, Laura Baldino1, Vasilis Hristidis1, Sarat Chandarlapaty1,4, Omar Abdel-Wahab1, Christina Leslie2, Maurizio Scaltriti1,13, Eneda Toska7,12.   

Abstract

The phosphoinositide 3-kinase (PI3K) pathway regulates proliferation, survival, and metabolism and is frequently activated across human cancers. A comprehensive elucidation of how this signaling pathway controls transcriptional and cotranscriptional processes could provide new insights into the key functions of PI3K signaling in cancer. Here, we undertook a transcriptomic approach to investigate genome-wide gene expression and transcription factor activity changes, as well as splicing and isoform usage dynamics, downstream of PI3K. These analyses uncovered widespread alternatively spliced isoforms linked to proliferation, metabolism, and splicing in PIK3CA-mutant cells, which were reversed by inhibition of PI3Kα. Analysis of paired tumor biopsies from patients with PIK3CA-mutated breast cancer undergoing treatment with PI3Kα inhibitors identified widespread splicing alterations that affect specific isoforms in common with the preclinical models, and these alterations, namely PTK2/FRNK and AFMID isoforms, were validated as functional drivers of cancer cell growth or migration. Mechanistically, isoform-specific splicing factors mediated PI3K-dependent RNA splicing. Treatment with splicing inhibitors rendered breast cancer cells more sensitive to the PI3Kα inhibitor alpelisib, resulting in greater growth inhibition than alpelisib alone. This study provides the first comprehensive analysis of widespread splicing alterations driven by oncogenic PI3K in breast cancer. The atlas of PI3K-mediated splicing programs establishes a key role for the PI3K pathway in regulating splicing, opening new avenues for exploiting PI3K signaling as a therapeutic vulnerability in breast cancer. SIGNIFICANCE: Transcriptomic analysis reveals a key role for the PI3K pathway in regulating RNA splicing, uncovering new mechanisms by which PI3K regulates proliferation and metabolism in breast cancer. See related commentary by Claridge and Hopkins, p. 2216. ©2022 The Authors; Published by the American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35442400      PMCID: PMC9354703          DOI: 10.1158/0008-5472.CAN-22-0446

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   13.312


  50 in total

1.  The Akt-SRPK-SR axis constitutes a major pathway in transducing EGF signaling to regulate alternative splicing in the nucleus.

Authors:  Zhihong Zhou; Jinsong Qiu; Wen Liu; Yu Zhou; Ryan M Plocinik; Hairi Li; Qidong Hu; Gourisanker Ghosh; Joseph A Adams; Michael G Rosenfeld; Xiang-Dong Fu
Journal:  Mol Cell       Date:  2012-06-21       Impact factor: 17.970

Review 2.  Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond.

Authors:  Michael Platten; Ellen A A Nollen; Ute F Röhrig; Francesca Fallarino; Christiane A Opitz
Journal:  Nat Rev Drug Discov       Date:  2019-05       Impact factor: 84.694

3.  An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice.

Authors:  Kathryn M Kinross; Karen G Montgomery; Margarete Kleinschmidt; Paul Waring; Ivan Ivetac; Anjali Tikoo; Mirette Saad; Lauren Hare; Vincent Roh; Theo Mantamadiotis; Karen E Sheppard; Georgina L Ryland; Ian G Campbell; Kylie L Gorringe; James G Christensen; Carleen Cullinane; Rodney J Hicks; Richard B Pearson; Ricky W Johnstone; Grant A McArthur; Wayne A Phillips
Journal:  J Clin Invest       Date:  2012-01-03       Impact factor: 14.808

Review 4.  Alternative splicing as a regulator of development and tissue identity.

Authors:  Francisco E Baralle; Jimena Giudice
Journal:  Nat Rev Mol Cell Biol       Date:  2017-05-10       Impact factor: 94.444

5.  E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo.

Authors:  Y Ozawa; N H Sugi; T Nagasu; T Owa; T Watanabe; N Koyanagi; H Yoshino; K Kitoh; K Yoshimatsu
Journal:  Eur J Cancer       Date:  2001-11       Impact factor: 9.162

Review 6.  The guanine nucleotide-binding switch in three dimensions.

Authors:  I R Vetter; A Wittinghofer
Journal:  Science       Date:  2001-11-09       Impact factor: 47.728

7.  Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients.

Authors:  André Kahles; Kjong-Van Lehmann; Nora C Toussaint; Matthias Hüser; Stefan G Stark; Timo Sachsenberg; Oliver Stegle; Oliver Kohlbacher; Chris Sander; Gunnar Rätsch
Journal:  Cancer Cell       Date:  2018-08-02       Impact factor: 31.743

8.  Contribution of the R-Ras2 GTP-binding protein to primary breast tumorigenesis and late-stage metastatic disease.

Authors:  Romain M Larive; Giulia Moriggi; Mauricio Menacho-Márquez; Marta Cañamero; Enrique de Álava; Balbino Alarcón; Mercedes Dosil; Xosé R Bustelo
Journal:  Nat Commun       Date:  2014-05-14       Impact factor: 14.919

Review 9.  PI3K in stemness regulation: from development to cancer.

Authors:  Ralitsa R Madsen
Journal:  Biochem Soc Trans       Date:  2020-02-28       Impact factor: 5.407

Review 10.  The therapeutic potential of targeting tryptophan catabolism in cancer.

Authors:  Luis F Somarribas Patterson; Soumya R Mohapatra; Dyah L Dewi; Christiane A Opitz; Ahmed Sadik; Michael Platten; Saskia Trump
Journal:  Br J Cancer       Date:  2019-12-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.